Invivyd (IVVD) Projected to Post Earnings on Thursday

Invivyd (NASDAQ:IVVD) will likely be posting its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Invivyd to post earnings of ($0.25) per share and revenue of $13.57 million for the quarter.

Invivyd Stock Performance

NASDAQ:IVVD opened at $0.72 on Thursday. Invivyd has a 52 week low of $0.35 and a 52 week high of $4.74. The firm has a market cap of $86.12 million, a price-to-earnings ratio of -0.37 and a beta of 0.09. The firm’s 50-day simple moving average is $0.97 and its 200 day simple moving average is $0.87.

Analyst Ratings Changes

Several analysts have recently weighed in on IVVD shares. D. Boral Capital reiterated a “buy” rating and issued a $9.00 price objective on shares of Invivyd in a research note on Wednesday, March 5th. Morgan Stanley reduced their price objective on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research note on Wednesday, November 20th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Invivyd in a research report on Monday, February 24th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $7.89.

Insider Activity at Invivyd

In related news, Director Terrance Mcguire sold 75,776 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $0.45, for a total value of $34,099.20. Following the transaction, the director now owns 3,492,498 shares in the company, valued at $1,571,624.10. The trade was a 2.12 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 365,943 shares of company stock worth $171,220 in the last three months. 17.90% of the stock is owned by insiders.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.